The Wall Street Journal reported Gilead's Tamiflu royalties rose to $246.3 million from $33.2 million for the Quarter. This should be reflected in Biotas royalties.Cheers
NTI Neurotech knocked back by FDA as agency declares target condition not rare enough for special status